FDA setback the last straw for Merck's women's health portfolio?
This article was originally published in Scrip
Executive Summary
Merck admission that it has received a complete response letter from the FDA for its novel contraceptive Nomac E2 (nomegestrol acetate/17 beta estradiol) may spell the end for more than just this product, analysts at Datamonitor say.